The impact of glucocorticoids on the efficacy of JAK inhibitors or non-TNF-targeted biologics in RA
Open Access
- 17 November 2025
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Abstract
Objectives: To evaluate the impact of oral low-dose glucocorticoids (GCs) on the effectiveness of Janus kinase inhibitors (JAKis) compared with non-TNF-targeted bDMARDs (other mechanisms of action [OMA] including tocilizumab, abatacept and rituximab) in RA patients with inadequate response to TNF inhibitors (TNFi-IRs). Methods: Single-centre, retrospective cohort study. The primary outcome was the good EULAR response at 6, 12 and 24 months. Secondary outcomes included treatment discontinuation and remission rates. Statistical analyses included structural equation modeling (SEM), competing risks analysis and linear mixed-effects models. Results: The study included 299 patients (JAKi = 161, OMA = 138). Baseline GC use was similar between the groups (JAKi = 66.5%, OMA = 76%; P = 0.089; mean (SD) daily dose 4.4 (5.5) vs 4.9 (4.5) mg/d; P = 0.355). The proportion of GC users treated with JAKi or OMA at 6, 12 and 24 months was 49.7% vs 63.8% (P = 0.036), 37.3% vs 40.6% (P = 0.161) and 27.3% vs 34.1% (P = 0.430). No statistically significant differences in GC dose reduction were observed between the two groups across any time interval. The EULAR response improved at 24 months, with JAKi outperforming OMA (SEM; P = 0.040). GC dosage at 6 months negatively affected the 24-month outcome (β = −0.456, P = 0.020). DAS28-CRP remission was more frequent in the JAKi group (P < 0.05), while discontinuation rates were similar (HR = 1.49, P = 0.34). Conclusion: JAKi did not show superiority over OMA regarding steroid-sparing effects; however, JAKi yielded higher remission rates. Exposure to GC at 6 months predicted poorer 24-month outcomes.Keywords
Funding Information
- Italian Ministry of Health (POS-T3-AN-14)
This publication has 36 references indexed in Scilit:
- Association of Cardiovascular Outcomes With Low‐Dose Glucocorticoid Prescription in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2024
- Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE StudyRheumatology and Therapy, 2024
- Remission or Not Remission, That’s the Question: Shedding Light on Remission and the Impact of Objective and Subjective Measures Reflecting Disease Activity in Rheumatoid ArthritisRheumatology and Therapy, 2022
- Methotrexate in early rheumatoid arthritis: Is the anchor drug still holding?Autoimmunity Reviews, 2022
- Risk for Herpes Zoster in Tofacitinib‐Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and GlucocorticoidsArthritis Care & Research, 2019
- Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEAClinical Rheumatology, 2017
- Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant TherapyArthritis & Rheumatology, 2017
- Time Trends in Glucocorticoid Use in Rheumatoid Arthritis: Results From a Population‐Based Inception Cohort, 1980–1994 Versus 1995–2007Arthritis Care & Research, 2014
- Effects of glucocorticoids on radiological progression in rheumatoid arthritisCochrane Database of Systematic Reviews, 2007
- COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief interventionArthritis & Rheumatism, 2002